申联生物表示，2025年度，公司持续拓展生物医药技术应用新领域，多措并举提升产品市场竞争力，公 司营销布局不断优化提升，产品进入大型养殖集团供应链体系取得积极进展，产品销售量增加。但由于 动保行业整体竞争较为激烈，疫苗产品单价下降，导致公司销售收入和毛利率较上年同期均略有下降。 由于客户延迟支付货款导致公司应收账款余额增大，公司计提的信用减值损失上升。另外，随着公司新 疫苗车间投入使用并转固，相关固定资产折旧额增加。 北京商报讯（记者 丁宁）1月23日晚间，申联生物（688098）发布2025年业绩预告显示，公司预计2025 年度实现归属净利润约-2000万元，与上年同期相比，减少亏损约2474万元，亏损幅度同比收窄约 55%。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 17.35 | -1.42% | 31.57万 | 5.51亿 | | 603566 | 普莱柯 | 13.78 | -0.72% | 5.94万 | 8171.47万 | | 600195 | 中牧股份 | 8.49 | -0.59% | 14.59万 | 1.23亿 | | 002868 | *ST绿康 | 37.28 | -0.43% | 8137.0 | 3038.12万 | | 300119 | 瑞普生物 | 20.38 | -0.39% | 4.53万 | 9258.76万 | | 002141 | 贤丰控股 | 4.19 | 0.00% | 154.61万 | 6.70亿 | | 688098 | 申联生物 | 9.97 | 0.10% | 5.22万 | 5205.80万 | | 002688 | 金河生物 | 6.39 | 0.16% | 13.54万 | 8616.98万 | | 688526 | ...

智通财经APP讯，申联生物(688098.SH)发布2025年年度业绩预告，预计2025年度实现归属于母公司所 有者的净利润约-2,000万元，与上年同期相比，减少亏损约2,474万元，亏损幅度同比收窄约55%。 在此情况下，公司适时调整经营策略，市场拓展进一步聚焦客户需求，多联多价疫苗等产品研发取得积 极进展，猪瘟基因工程亚单位疫苗、猪链球菌病/传染性胸膜肺炎二联疫苗等产品接连上市，产品种类 更加丰富;内部管理更加精干高效，期间费用总额较上年同期明显下降，归属母公司净利润亏损减少约 55%。 报告期初，公司投资参股创新药公司扬州世之源生物科技有限责任公司(以下简称"世之源")，世之源正 在开展创新药的临床研究并进行持续投入，对公司净利润造成一定影响。为全面实现人药和动保双主业 协同发展的模式，公司拟收购世之源的控股权，未来公司将以世之源作为新型生物医药技术及人用创新 药推进平台，充分发挥公司前沿生物技术及生产优势在人用创新药领域的延展应用，快速推进艾滋病单 抗等多个创新药的研发及上市。 报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润出现 亏损，主要基于以下原因：202 ...

智通财经APP讯，申联生物(688098.SH)发布2025年年度业绩预告，预计2025年度实现归属于母公司所 有者的净利润约-2,000万元，与上年同期相比，减少亏损约2,474万元，亏损幅度同比收窄约55%。 报告期初，公司投资参股创新药公司扬州世之源生物科技有限责任公司(以下简称"世之源")，世之源正 在开展创新药的临床研究并进行持续投入，对公司净利润造成一定影响。为全面实现人药和动保双主业 协同发展的模式，公司拟收购世之源的控股权，未来公司将以世之源作为新型生物医药技术及人用创新 药推进平台，充分发挥公司前沿生物技术及生产优势在人用创新药领域的延展应用，快速推进艾滋病单 抗等多个创新药的研发及上市。 在此情况下，公司适时调整经营策略，市场拓展进一步聚焦客户需求，多联多价疫苗等产品研发取得积 极进展，猪瘟基因工程亚单位疫苗、猪链球菌病/传染性胸膜肺炎二联疫苗等产品接连上市，产品种类 更加丰富;内部管理更加精干高效，期间费用总额较上年同期明显下降，归属母公司净利润亏损减少约 55%。 报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润出现 亏损，主要基于以下原因：202 ...

公司预计2025年度归属于母公司所有者的扣除非经常性损益后的净利润约-2350万元，与上年同期相 比，减少亏损约2488万元，亏损幅度同比收窄约51%。 格隆汇1月23日丨申联生物(688098.SH)公布，公司预计2025年度实现归属于母公司所有者的净利润 约-2000万元，与上年同期相比，减少亏损约2474万元，亏损幅度同比收窄约55%。 ...

证券代码：688098 证券简称：申联生物 公告编号：2026-001 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 1.2024年度，公司归属于母公司所有者的净利润：-4,474.01万元；归属于母 公司所有者的扣除非经常性损益的净利润：-4,837.65万元。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1.公司预计 2025 年度实现归属于母公司所有者的净利润约-2,000 万元，与 上年同期相比，减少亏损约 2,474 万元，亏损幅度同比收窄约 55%。 2.公司预计2025年度归属于母公司所有者的扣除非经常性损益后的净利润 约-2,350万元，与上年同期相比，减少亏损约2,488万元，亏损幅度同比收窄约 51%。 四、风险提示 本次预测的业绩是公司财务部门基于年度经营情况和自身专业判断进行的 初步测算，未经会计师事务所审计，公司尚未发现影响本次业绩预告内容准确 性的其他重大不确定性因素。 ...

Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

Core Viewpoint - The animal health sector experienced a decline of 0.65% on January 21, with Huisheng Biological leading the drop. The Shanghai Composite Index rose by 0.08%, while the Shenzhen Component Index increased by 0.7 [1] Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Shunlian Biological up by 4.20% and Huisheng Biological down by 6.19% [1][2] - The trading volume for Huisheng Biological was 419,900 shares, with a transaction value of 1.192 billion yuan, indicating significant market activity despite the decline [2] Group 2: Capital Flow - The animal health sector saw a net inflow of 9.6935 million yuan from institutional investors, while retail investors experienced a net outflow of 73.8174 million yuan, suggesting a shift in investor sentiment [2][3] - Among individual stocks, Xianfeng Holdings had a net inflow of 15.1182 million yuan from institutional investors, while Huisheng Biological saw a net outflow of 42.2249 million yuan from retail investors [3]

Market Overview - The animal health sector increased by 3.21% on January 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] Stock Performance - Huisheng Biological (300871) closed at 28.16, up 8.18% with a trading volume of 331,800 shares [1] - Zhongmu Co., Ltd. (600195) closed at 8.49, up 7.88% with a trading volume of 435,600 shares [1] - Other notable performers include: - Biological Co. (600201) at 18.28, up 3.80% [1] - Jinhai Biological (002688) at 6.45, up 3.53% [1] - Shunlian Biological (688098) at 9.91, up 3.23% [1] Capital Flow - The animal health sector saw a net inflow of 175 million yuan from institutional investors, while retail investors experienced a net outflow of 171 million yuan [2] - The main capital flow details include: - Huisheng Biological had a net outflow of 59.49 million yuan from institutional investors [3] - Biological Co. had a net inflow of 58.13 million yuan from institutional investors [3] - Jinhai Biological experienced a net inflow of 35.35 million yuan from institutional investors [3]

Core Viewpoint - The animal health sector experienced a rise of 0.93% on January 16, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4101.91, down 0.26% [1]. - The Shenzhen Component Index closed at 14281.08, down 0.18% [1]. Group 2: Individual Stock Performance - BioShares (600201) led the gains with a closing price of 17.61, up 3.53%, and a trading volume of 480,000 shares, amounting to a transaction value of 840 million yuan [1]. - Other notable performers included: - Huisheng Bio (300871) at 26.03, up 1.36%, with a transaction value of 434 million yuan [1]. - Xianfeng Holdings (002141) at 3.76, up 1.35%, with a transaction value of 8.13 million yuan [1]. - Ruipu Bio (300119) at 20.15, up 0.90%, with a transaction value of 110 million yuan [1]. - Shunlian Bio (688098) at 9.60, up 0.63%, with a transaction value of 40.84 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 112 million yuan from institutional investors, while retail investors experienced a net outflow of 68.65 million yuan [2]. - The capital flow for individual stocks showed: - BioShares had a net inflow of 75.95 million yuan from institutional investors [3]. - Huisheng Bio had a net inflow of 19.63 million yuan from institutional investors [3]. - Xianfeng Holdings had a net inflow of 16.40 million yuan from institutional investors [3].